Notice NOT-DK-20-051 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-103 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/?R?e?s?e?a?r?c?h staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-21-102 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving m?o?r?e? ?t?h?a?n? ?o?n?e? clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-21-101 from the NIH Guide for Grants and Contracts. NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.

Notice NOT-OD-21-045 from the NIH Guide for Grants and Contracts

Notice NOT-OD-21-044 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-21-016 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD.

Funding Opportunity RFA-DA-21-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD.

Notice NOT-MD-21-009 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Head of Human Resources, EMBL-EBI Location: Cambridge, Cambridgeshire, England

Funding Opportunity PAR-21-100 from the NIH Guide for Grants and Contracts. This FOA is intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders. Proposed R01 projects can investigate how music is processed by or modifies the brain, or how it affects specific biological functions during childhood development and learning, adulthood, and aging. Projects can also include preliminary interventions that provide a basis for therapeutic interventions. When appropriate, collaborations among basic researchers, technology developers, music intervention experts, or other clinical researchers are highly encouraged.

Funding Opportunity PAR-21-099 from the NIH Guide for Grants and Contracts. This FOA is intended to: (1) increase our understanding of how music affects the brain when it is used therapeutically and/or (2) use that knowledge to better develop evidence-based music interventions to enhance health or treat specific diseases and disorders.

Candidates should have experience working with common computer applications used in lab operations and data analysis (Word, PowerPoint, Excel, etc.).
From University of Wisconsin–Madison - Wed, 23 Dec 2020 00:57:51 GMT - View all Madison, WI jobs

Up to £45,000 plus full benefits package: Singular Talent: NGS expert with a drive to contribute to truly novel drug research? Read on..... Oxford, Oxfordshire (GB)

Funding Opportunity RFA-DA-21-032 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.

Funding Opportunity RFA-DA-21-031 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids.

Notice NOT-OD-21-042 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Bioinformatician (Open Targets) Location: Cambridge, Cambridgeshire, England

Notice NOT-MH-21-140 from the NIH Guide for Grants and Contracts

Notice NOT-MH-21-136 from the NIH Guide for Grants and Contracts